Sara, S., Shahyan, B.S., Yas, S., Elsa, K., Peyman, B., & Jane, Y. (2026). Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis.. The Journal of thoracic and cardiovascular surgery.
Sara S, Shahyan BS, Yas S, Elsa K, Peyman B, Jane Y. Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis.. The Journal of thoracic and cardiovascular surgery. 2026; PMID: 42107635
Sara S, Shahyan BS, Yas S, et al. Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis.[J]. The Journal of thoracic and cardiovascular surgery. 2026.
@article{sara2026,
author = {Sakowitz Sara and Bakhtiyar Syed Shahyan and Sanaiha Yas and Kronen Elsa and Benharash Peyman and Yanagawa Jane},
title = {Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis.},
journal = {The Journal of thoracic and cardiovascular surgery},
year = {2026},
note = {PMID: 42107635},
}
TY - JOUR AU - Sakowitz Sara AU - Bakhtiyar Syed Shahyan AU - Sanaiha Yas AU - Kronen Elsa AU - Benharash Peyman AU - Yanagawa Jane TI - Neoadjuvant Chemoradiation versus Perioperative Chemotherapy in Locally Advanced Resectable Esophageal Adenocarcinoma: A National Analysis. T2 - The Journal of thoracic and cardiovascular surgery PY - 2026 AN - PMID:42107635 ER -
There is ongoing debate regarding the optimal multimodal treatment for patients with resectable locally advanced esophageal adenocarcinoma, with the recent ESOPEC trial suggesting perioperative chemotherapy to yield superior survival compared to CROSS neoadjuvant chemoradiation. Providing a contemporary perspective, we sought to elucidate survival outcomes among a national cohort.